Table 1 Characteristics of studies included in the meta-analysis.
Study (year) | Study type | Location | Treatment | No. of patients | Mean age(range) | Gender (M/F) | HBV DNA (log10 copies/mL) | HBeAg positive | Normal ALT (No.) | Nucleos(t)ide Drug history | Study duration | Jadad score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tan, J | Non | United States | TDF | 10 | 47.7 (35-72) | 11/2b | 4.4-10 | 11/13d | 1/10 | ADV | 27 | 1 |
(2008) | RCT | FTC/TDF | 3 | 61.6 (57–66) | 5.0–6.3 | 0/3 | months | |||||
Liaw, YF | RCT | 39 study centers | TDF | 45 | 52 (48–57)a | 37/8 | 4.7–6.6a | 14/45 | 18/45 | 19/45e 9/45f | 48 | 4 |
(2011) | in 5 region | FTC/TDF | 45 | 50 (42–58)1 | 40/5 | 4.5–7.3a | 18/45 | 18/45 | 17/45e 10/45f | weeks | ||
Berg, T | RCT | 28 study centers | TDF | 53 | 40 (18–59) | 38/15 | 3.41–9.57 | 38/53 | 26/53 | ADV | 48 | 4 |
(2010) | in 4 regions | FTC/TDF | 52 | 39 (19–59) | 42/10 | 2.23–9.47 | 39/52 | 26/52 | weeks | |||
Chan, HLY | RCT | 34 study centers | TDF | 64 | 33 (18–62) | 31/33 | 8.02–10.22 | 63/64 | 60/64 | Naïve | 192 | 4 |
(2014) | in 11 countries | FTC/TDF | 62 | 33 (18–58) | 31/31 | 7.79–9.87 | 62/62 | 56/62 | weeks | |||
Fung, S | RCT | 62 study centers | TDF | 141 | 47.1 (unclear) | 104/37 | 5.64 ± 1.83c | 65/141 | 62/141 | LAM | 96 | 4 |
(2014) | in 3 regions | FTC/TDF | 139 | 46.3 (unclear) | 107/32 | 5.77± 1.97c | 68/139 | 56/139 | weeks |
